Adding liraglutide to the backbone therapy of biguanide in patients with coronary artery disease and newly diagnosed type-2 diabetes (the AddHope2 study): A randomised controlled study protocol

BMJ Open

Volumn 4, Issue 7, 2014, Pages

  Anholm, Christian ^a   Kumarathurai, Preman ^a   Klit, Malene S ^a   Kristiansen, Ole P ^a   Nielsen, Olav W ^a   Ladelund, Steen ^a   Madsbad, Sten ^a   Sajadieh, Ahmad ^a   Haugaard, Steen B ^a  

^a Mental Health Center Glostrup   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; C REACTIVE PROTEIN; DOBUTAMINE; FATTY ACID; GLUCAGON; GLUCOSE; INSULIN; INTERLEUKIN 6; LIRAGLUTIDE; METFORMIN; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; ANTIDIABETIC AGENT;

ADIPOSE TISSUE; ARTICLE; BLOOD ANALYSIS; BLOOD PRESSURE MEASUREMENT; CARDIAC PATIENT; CELL FUNCTION; CLINICAL ARTICLE; CLINICAL PROTOCOL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CROSSOVER PROCEDURE; DIABETIC PATIENT; DOUBLE BLIND PROCEDURE; EXERCISE TEST; EXERCISE TOLERANCE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FILLING PRESSURE; HEART LEFT VENTRICLE FUNCTION; HEART MOVEMENT; HEART RATE VARIABILITY; HOLTER MONITORING; HUMAN; HUMAN TISSUE; INFLAMMATION; INSULIN SENSITIVITY; INTERVENTION STUDY; INTRAVENOUS GLUCOSE TOLERANCE TEST; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT DEPRESSION; STRESS ECHOCARDIOGRAPHY; SUBCUTANEOUS FAT; SYSTOLE; TEST MEAL; URINALYSIS; COMBINATION DRUG THERAPY; COMPLICATION; DIABETES MELLITUS, TYPE 2; METHODOLOGY;

CORONARY ARTERY DISEASE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE; METFORMIN; RESEARCH DESIGN;

EID: 84904490558     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2014-005942     Document Type: Article

References (45)

1. Fox CS, Coady S, Sorlie PD, et al. Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation 2007;115:1544-50. (Pubitemid 46648639)
2. Morrish NJ, Wang SL, Stevens LK, et al. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001;44(Suppl 2):S14-21. (Pubitemid 32844108)
3. Lenzen M, Ryden L, Ohrvik J, et al. Diabetes known or newly detected, but not impaired glucose regulation, has a negative influence on 1-year outcome in patients with coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart. Eur Heart J 2006;27:2969-74. (Pubitemid 44950440)
4. Sauer WH, Cappola AR, Berlin JA, et al. Insulin sensitizing pharmacotherapy for prevention of myocardial infarction in patients with diabetes mellitus. Am J Cardiol 2006;97:651-4. (Pubitemid 43255033)
5. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-79.
6. Vitale C, Mercuro G, Cornoldi A, et al. Metformin improves endothelial function in patients with metabolic syndrome. J Intern Med 2005;258:250-6. (Pubitemid 41243057)
7. De Aguiar LGK. Metformin improves endothelial vascular reactivity in first-degree relatives of type 2 diabetic patients with metabolic syndrome and normal glucose tolerance. Diabetes Care 2006;29:1083-9.
8. Mudaliar S, Henry RR. Effects of incretin hormones on beta-cell mass and function, body weight, and hepatic and myocardial function. Am J Med 2010;123:S19-27.
9. Green BD, Hand KV, Dougan JE, et al. GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP. Arch Biochem Biophys 2008;478:136-42.
10. Nyström T, Gonon AT, Sjöholm A, et al. Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. Regul Pept 2005;125:173-7. (Pubitemid 39593722)
11. Ozyazgan S, Kutluata N, Afşar S, et al. Effect of glucagon-like peptide-1 (7-36) and exendin-4 on the vascular reactivity in streptozotocin/nicotinamide-induced diabetic rats. Pharmacology 2005;74:119-26. (Pubitemid 40981097)
12. Sokos GG, Nikolaidis LA, Mankad S, et al. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 2006;12:694-9. (Pubitemid 44881367)
13. Halbirk M, Nørrelund H, Møller N, et al. Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure. Am J Physiol Heart Circ Physiol 2010;298:H1096-102.
14. Bose AK, Mocanu MM, Carr RD, et al. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005;54:146-51. (Pubitemid 40105106)
15. Noyan-Ashraf MH, Momen MA, Ban K, et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 2009;58:975-83.
16. Lønborg J, Vejlstrup N, Kelbæk H, et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J 2012;33:1491-9.
17. Read PA, Khan FZ, Heck PM, et al. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circ Cardiovasc Imaging 2010;3:195-201.
18. Devereux RB, Roman MJ, Paranicas M, et al. Impact of diabetes on cardiac structure and function: the strong heart study. Circulation 2000;101:2271-6. (Pubitemid 30317129)
19. Sozzi FB, Elhendy A, Roelandt JRTC, et al. Prognostic value of dobutamine stress echocardiography in patients with diabetes. Diabetes Care 2003;26:1074-8. (Pubitemid 36929251)
20. Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev 2012;33:187-215.
21. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403. (Pubitemid 34437694)
22. Lund A, Knop FK, Vilsbøll T. Emerging GLP-1 receptor agonists. Expert Opin Emerg Drugs 2011;16:607-18.
23. Vilsbøll T, Christensen M, Junker AE, et al. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012;344:d7771.
24. Zander M, Madsbad S, Madsen JL, et al. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002;359:824-30. (Pubitemid 34233752)
25. Meneilly GS, Greig N, Tildesley H, et al. Effects of 3 months of continuous subcutaneous administration of glucagon-like peptide 1 in elderly patients with type 2 diabetes. Diabetes Care 2003;26:2835-41. (Pubitemid 37205555)
26. Marso SP, Poulter NR, Nissen SE, et al. Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. Am Heart J 2013;166:823-30.e5.
27. Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): a trial to evaluate cardiovascular outcomes after treatment with exenatide once weekly in patients with type 2 diabetes mellitus. 2012. http://clinicaltrials.gov/show/ NCT01144338
28. Bergman RN, Ider YZ, Bowden CR, et al. Quantitative estimation of insulin sensitivity. Quantitative estimation of insulin sensitivity. Am J Physiol Endocrinol Metab 1979;236:E667-77.
29. Hovorka R, Koukkou E, Southerden D, et al. Measuring pre-hepatic insulin secretion using a population model of C-peptide kinetics: accuracy and required sampling schedule. Diabetologia 1998;41:548-54. (Pubitemid 28206825)
30. Hovorka R, Soons PA, Young MA. ISEC: a program to calculate insulin secretion. Comput Methods Programs Biomed 1996;50:253-64. (Pubitemid 26308809)
31. Toffolo G, Campioni M, Basu R, et al. A minimal model of insulin secretion and kinetics to assess hepatic insulin extraction. Am J Physiol Endocrinol Metab 2006;290:E169-76.
32. Boston RC, Moate PJ. NEFA minimal model parameters estimated from the oral glucose tolerance test and the meal tolerance test. Am J Physiol Regul Integr Comp Physiol 2008;295:R395-403.
33. Boston RC, Moate PJ. A novel minimal model to describe NEFA kinetics following an intravenous glucose challenge. Am J Physiol Regul Integr Comp Physiol 2008;294:R1140-7. (Pubitemid 351490632)
34. Utzschneider KM, Tong J, Montgomery B, et al. The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose. Diabetes Care 2008;31:108-13.
35. Mari A, Pacini G. Methods for the assessment of beta-cell function in vivo. In: Roden M. ed. Clinical diabetes research - methods and techniques. Wiley, 2007:13-14.
36. Pacini G, Tonolo G, Sambataro M, et al. Insulin sensitivity and glucose effectiveness: minimal model analysis of regular and insulin-modified FSIGT. Am J Physiol 1998;274:E592-9.
37. Sicari R, Nihoyannopoulos P, Evangelista A, et al. Stress echocardiography expert consensus statement: European Association of Echocardiography (EAE) (a registered branch of the ESC). Eur J Echocardiogr 2008;9:415-37.
38. Becher H, Chambers J, Fox K, et al. BSE procedure guidelines for the clinical application of stress echocardiography, recommendations for performance and interpretation of stress echocardiography: a report of the British Society of Echocardiography Policy Committee. Heart 2004;90(Suppl 6):vi23-30. (Pubitemid 39626299)
39. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification. Eur J Echocardiogr 2006;7:79-108. (Pubitemid 43257193)
40. Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989;2:358-67.
41. Hills M, Armitage P. The two-period cross-over clinical trial. Br J Clin Pharmacol 1979;8:7-20. (Pubitemid 9234327)
42. Senn S. Cross-over trials in clinical research. 2nd edn. Chichester: John Wiley and Son, 2002.
43. Akehi Y, Yoshimatsu H, Kurokawa M, et al. VLCD-induced weight loss improves heart rate variability in moderately obese Japanese. Exp Biol Med (Maywood) 2001;226:440-5. (Pubitemid 32506369)
44. Haugaard SB, Vaag A, Høy C-E, et al. Desaturation of skeletal muscle structural and depot lipids in obese individuals during a very-low-calorie diet intervention. Obesity (Silver Spring) 2007;15:117-25. (Pubitemid 46219791)
45. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med 2010;152:726-32.